Patient Care Staff

Elinzanetant reduced VMS frequency and intensity, and improved sleep and quality of life, according to the meta-analysis to be presented at the ACOG 2025 meeting.

An FDA decision on GSK's Shingrix application is expected by June 20, 2025.

Mineralys Therapeutics also expects topline data from its phase 2 study of lorundrostat for the treatment of uncontrolled hypertension or resistant hypertension when used as an add-on therapy.

Marketed as Omvoh, the therapy is already approved as a first-in-class treatment for moderately to severely active ulcerative colitis.

Early proof-of-concept phase 1a data from the trial is anticipated in the third quarter of 2025.

FDA action date set for July 26, 2025.

If approved, neffy 1 mg will be the only needle-free epinephrine treatment available for the younger, school-aged population.

The acquisition brings lumateperone, known as Caplyta, and the clinical-stage agent ITI-1284, for generalized anxiety disorder and Alzheimer's agitation, into the J&J fold.

The planned Phase 2 trial in IPF will focus on assessing MTX-463’s safety, pharmacokinetics, and efficacy.

Johnson & Johnson's posdinemab aims to slow tau pathology in early and preclinical Alzheimer’s disease populations.

NX-102 SL is a non-opioid, centrally acting analgesic, granted Fast Track designation by FDA.

A phase 1b and Phase 2 study are up next for the novel potential MDD treatment.

A summary of new data presented at the 2024 American College of Allergy, Asthma & Immunology Annual Scientific Meeting.

The caffeine in an average cup o' joe delivers the ideal morning jolt, but concentrated amounts can be fatal. How little is dangerous? Find out, here.

When to test, how long to treat, what adjustments to make to avoid dangerous drug interactions;  test your HCV IQ with a short quiz on a range of topics.

Are you up-to-date on the wide variety and variable potency of cannabis products your patients may use? Test yourself and find out.

Modern ICDs have built-in protection from interference by most current technologies. But do you know which ones could be problematic for your patients?

It's a short quiz but it covers a broad range of knowledge about testing, treatment, and drug choices in persons with HCV infection.